Expression of Confidence in CollPlant: Investment agreement signed with Meitav-Dash including shares and warrants for NIS 4.8 million

Expression of Confidence in CollPlant: Investment agreement signed with Meitav-Dash including shares and warrants for NIS 4.8 million

Assuming full exercise of Meitav-Dashs warrants, the Company will raise an additional NIS 9.5 million

The Company is in contact with other parties to invest in the Company at similar terms

Ness Ziona, November 9, 2017, CollPlant (TASE: CLPT) – a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, “rhCollagen”), announces that it has signed a private restricted investment agreement with Meitav-Dash, one of the Company’s largest shareholders. As part of the investment agreement, which includes shares and warrants, the Company will immediately raise NIS 4.8 million, and upon full exercise of the warrants, a further NIS 9.8 million.

Last month, the Company announced completion of the first stage of a USD 2 million investment agreement with American investors, as part of an overall investment agreement of USD 5 million.

About CollPlant

CollPlant is a regenerative medicine company leveraging its proprietary, plant-based recombinant human collagen (rhCollagen) technology for the development and commercialization of tissue repair products, initially for the orthobiologics, 3D Bio-printing of tissue and organs, and advanced wound care markets. The Company’s cutting-edge technology is designed to generate and process proprietary rhCollagen, among other patent-protected recombinant proteins. Given that CollPlant’s rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company’s broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix®STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; and Vergenix®FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds.

CollPlant’s business strategy includes proprietary development and manufacture of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacture and marketing of additional products.

For more information about CollPlant, visit

Contact at CollPlant:
Eran Rotem
Chief Financial Officer
Tel: +972-73-2325600/612

Contact at Rx Communications Group, LLC:
Paula Schwartz (for US Investors)
Senior Vice President
Tel: +1-917-322-2216

® 2015 CollPlant Ltd. All rights reserved. Version: CPW 02-16